We Work for Health | Washington

09/09/2026

"The U.S. market is therefore not simply a high-price market: brand-against-brand therapeutic competition progressively places pressure on innovators’ market share, net prices, and expected returns."

is bad for business:

Policy Brief: The Impact of Foreign Drug Adoption Delays on International Free Riding Policy Briefs International free riding in pharmaceutical innovation is commonly understood as foreign countries benefiting from new therapies while paying regulated prices below those in the United States. This po...

09/08/2026

Congress should be cautious about turning Most-Favored-Nation drug pricing into permanent law. Codification could lock in an opaque, foreign-reference pricing regime that may deliver headline savings while weakening U.S. biomedical innovation."

https://www.tampafp.com/op-ed-mfn-drug-pricing-is-a-shortcut-that-could-cost-patients-tomorrows-cures/

09/04/2026

"A statutory MFN regime would put U.S. reimbursement at the mercy of foreign governments’ pricing decisions. Those countries often achieve lower prices through health systems, coverage rules, and centralized negotiations that the U.S. does not replicate."

https://www.tampafp.com/op-ed-mfn-drug-pricing-is-a-shortcut-that-could-cost-patients-tomorrows-cures/

09/02/2026

"American healthcare costs so much and works so poorly is lack of transparency and accountability. Hospitals, insurance companies, and other middlemen weaponize the system’s legal and administrative complexity to maximize their profits."

is broken:

Why would a large urban hospital want to be considered rural?

08/31/2026

"Medical innovations, such as the skin cancer vaccine, are being created in spite of the political class, not because of it."

America is coming one step closer to taming cancer.

08/28/2026

"The share of early-stage drug programs originating in China has quadrupled, reaching a high of 35% in 2024...Projections indicate that Chinese drugs could make up 35% of FDA approvals by 2040 – a sevenfold increase from the current 5%."

https://www.washingtontimes.com/news/2026/aug/15/beat-china-america-must-first-cut-red-tape/

08/26/2026

"Patents don't increase the odds that an experimental drug will work. But they ensure that if a drug does work and win FDA approval, developers will have a chance to recoup their investments before generic competitors enter the market."

Invest in R&D:

There's never a good time to be diagnosed with cancer. But for the millions of Americans who'll receive that diagnosis this year, their odds of beating the disease have never been better. Consider how

08/24/2026

"The U.S. has long led the world in producing these breakthroughs because we reward risk-taking and innovation. Unfortunately, a misguided Biden-era policy now threatens to undermine that uniquely American success."

The punishes innovation: https://www.forbes.com/sites/steveforbes/2026/08/17/america-should-reward--not-penalize-better-medicines/

08/21/2026

"The higher a brand-name drug's revenue, the more generic or biosimilar competitors it is likely to attract. And more competitors push prices lower.

That is where the IRA creates a problem.

Medicare's price controls take effect before generic or biosimilar competition emerges. By pushing down a brand-name drug's revenue, the government essentially shrinks the prize available to future generic and biosimilar developers.."

The is bad for business: https://www.realclearhealth.com/articles/2026/08/13/how_price_controls_could_drive_up_long-term_drug_spending_1200176.html

08/19/2026

"Some nonprofit hospitals mark up steeply discounted drugs by hundreds of percent while patients pay full cost-sharing on those same drugs. Under current rules, almost no one can see which hospitals are doing what."

Close loopholes: https://www.washingtonexaminer.com/op-eds/4681897/340b-hospital-drug-discount-program-reform-trump-hhs/